151 related articles for article (PubMed ID: 9433654)
1. Effect of renal impairment on the pharmacokinetics of grepafloxacin.
Efthymiopoulos C; Bramer SL; Maroli A; Gambertoglio JG
Clin Pharmacokinet; 1997; 33 Suppl 1():32-8. PubMed ID: 9433654
[TBL] [Abstract][Full Text] [Related]
2. Effect of age and gender on the pharmacokinetics of grepafloxacin.
Efthymiopoulos C; Bramer SL; Maroli A
Clin Pharmacokinet; 1997; 33 Suppl 1():9-17. PubMed ID: 9433651
[TBL] [Abstract][Full Text] [Related]
3. Theophylline and warfarin interaction studies with grepafloxacin.
Efthymiopoulos C; Bramer SL; Maroli A; Blum B
Clin Pharmacokinet; 1997; 33 Suppl 1():39-46. PubMed ID: 9433655
[TBL] [Abstract][Full Text] [Related]
4. Grepafloxacin pharmacokinetics in individuals with hepatic dysfunction.
Efthymiopoulos C; Bramer SL; Maroli A; Flaherty JF; Wolfe E; Bass N; Somberg K
Clin Pharmacokinet; 1997; 33 Suppl 1():25-31. PubMed ID: 9433653
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males.
Efthymiopoulos C; Bramer SL; Maroli A
Clin Pharmacokinet; 1997; 33 Suppl 1():1-8. PubMed ID: 9433650
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of grepafloxacin.
Efthymiopoulos C
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():35-43. PubMed ID: 9484872
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects.
Kozawa O; Uematsu T; Matsuno H; Niwa M; Nagashima S; Kanamaru M
Antimicrob Agents Chemother; 1996 Dec; 40(12):2824-8. PubMed ID: 9124849
[TBL] [Abstract][Full Text] [Related]
8. Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function.
Nilsen OG; Saltvedt E; Walstad RA; Marstein S
Am J Med; 1992 Apr; 92(4A):38S-40S. PubMed ID: 1316068
[TBL] [Abstract][Full Text] [Related]
9. Effect of food and gastric pH on the bioavailability of grepafloxacin.
Efthymiopoulos C; Bramer SL; Maroli A
Clin Pharmacokinet; 1997; 33 Suppl 1():18-24. PubMed ID: 9433652
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
[TBL] [Abstract][Full Text] [Related]
11. Multiple-dose pharmacokinetics of rufloxacin in patients with cirrhosis.
Triger DR; Granai F; Woodcock J; Wise R; Imbimbo BP
Hepatology; 1993 Oct; 18(4):847-52. PubMed ID: 8406358
[TBL] [Abstract][Full Text] [Related]
12. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.
Nakashima M; Uematsu T; Kosuge K; Kusajima H; Ooie T; Masuda Y; Ishida R; Uchida H
Antimicrob Agents Chemother; 1995 Dec; 39(12):2635-40. PubMed ID: 8592993
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of temafloxacin in patients with liver impairment.
Granneman GR; Mahr G; Locke C; Nickel P; Kirch W; Fabian W; Kinzig M; Naber KG; Sörgel F
Clin Pharmacokinet; 1992; 22 Suppl 1():24-32. PubMed ID: 1319868
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis.
Forrest A; Chodosh S; Amantea MA; Collins DA; Schentag JJ
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():45-57. PubMed ID: 9484873
[TBL] [Abstract][Full Text] [Related]
15. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability and pharmacokinetics of the new long-acting quinolone DW-116 after single and multiple dosing in healthy subjects.
Meyerhoff C; Dilger C; Yoon SJ; Chung YH; Lee DK; Lee CW; Ryu JM; Choi MS; Pabst G; Reh C
J Antimicrob Chemother; 1998 Sep; 42(3):349-61. PubMed ID: 9786475
[TBL] [Abstract][Full Text] [Related]
17. Grepafloxacin--a new fluoroquinolone.
Med Lett Drugs Ther; 1998 Jan; 40(1019):17-8. PubMed ID: 9465856
[No Abstract] [Full Text] [Related]
18. Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin.
Child J; Andrews JM; Wise R
Antimicrob Agents Chemother; 1995 Feb; 39(2):513-5. PubMed ID: 7726523
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of sparfloxacin in patients with renal impairment.
Fillastre JP; Montay G; Bruno R; Etienne I; Dhib M; Vivier N; Le Roux Y; Guimart C; Gay G; Schott D
Antimicrob Agents Chemother; 1994 Apr; 38(4):733-7. PubMed ID: 8031038
[TBL] [Abstract][Full Text] [Related]
20. Distribution characteristics of levofloxacin and grepafloxacin in rat kidney.
Ito T; Yano I; Masuda S; Hashimoto Y; Inui K
Pharm Res; 1999 Apr; 16(4):534-9. PubMed ID: 10227708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
